Cannabinoid

A cannabinoid is a psychoactive (or, in some cases, non-psychoactive) substance that acts on the endocannabinoid system through the cannabinoid type 1 (CB₁) and type 2 (CB₂) receptors.^[1] The class is defined by its pharmacological target rather than by any single chemical scaffold, which is why otherwise structurally unrelated compounds share its name.

Most cannabinoids converge on the same molecular endpoint: agonism (or, for cannabidiol, negative modulation) at the CB₁ and CB₂ receptors, both class A G protein-coupled receptors that couple predominantly to inhibitory G_i/o proteins and reduce intracellular cyclic AMP.^[3]

CB₁ is densely expressed in the basal ganglia, hippocampus, cerebral cortex, and cerebellum — distributions that map onto the class's signature effects on memory, mood, coordination, and reward. CB₂ is concentrated in immune tissues and does not drive the primary psychoactive profile.

The most pharmacologically consequential within-class distinction is intrinsic efficacy. Phytocannabinoids such as Δ9-THC are CB₁ partial agonists, which leaves endogenous tone partly intact and imposes a ceiling on the effect. Most synthetic cannabinoids in the class are CB₁ full agonists with higher affinity and no comparable ceiling — the primary mechanistic reason their toxicity profile is more severe and their dose-response less predictable.^[2]

The endogenous system these compounds engage uses two main ligands — anandamide and 2-arachidonoylglycerol — produced on demand from membrane lipids and rapidly degraded. Exogenous cannabinoids differ from these endogenous signals by acting more diffusely and persisting far longer at the receptor, which is why their effects extend well beyond the brief, local signaling that the endocannabinoid system normally produces.^[1]

Members span two functionally distinct subgroups — plant-derived phytocannabinoids and laboratory-synthesized full agonists — that share a receptor target but differ markedly in efficacy, predictability, and clinical profile.

Across the class, members differ in receptor efficacy, in the presence or absence of modulating constituents like CBD, and in the predictability of their dose-response. Synthetic cannabinoids in particular lack any plant-source CBD to attenuate their effects and are not detected by standard cannabis immunoassay drug screening — a clinically important distinction.^[2]

Across the class, the subjective trajectory tracks deepening CB₁ engagement as exposure rises, with the specific shape modulated by receptor efficacy and the presence of co-occurring constituents such as CBD.^[4]

The same receptor axis that produces the sought effects — relaxation, perceptual change, appetite — also produces the adverse ones at higher exposures, and the margin between them narrows as intrinsic efficacy rises. This is why synthetic full agonists, which lack the partial-agonist ceiling of Δ9-THC, produce qualitatively more severe presentations from comparable degrees of receptor engagement.^[2]

Tachycardia is the most consistent acute cardiovascular effect across the class. Synthetic members are additionally associated with myocardial ischemia, dysrhythmias including QT prolongation, hypertension, and in some case series acute coronary syndrome.^[6] Preexisting cardiovascular disease raises the risk substrate across the class.

Acute psychotic states can be precipitated by high-potency exposure, most pronounced with synthetic cannabinoids and with novel high-potency phytocannabinoid analogs, and concentrated in individuals with a personal or family history of psychotic illness and in adolescents.^[2]

Cannabinoid hyperemesis syndrome — cyclic, antiemetic-resistant nausea and vomiting that responds temporarily to hot bathing — is a distinctive pattern associated with prolonged heavy cannabinoid use; it resolves with sustained cessation and recurs rapidly with resumed use.

Combining cannabinoids with CNS depressants — alcohol, opioids, or benzodiazepines — amplifies sedation and cognitive-motor impairment and raises accident risk. The concern is most acute with synthetic full agonists, whose ceiling for CNS depression is higher than that of phytocannabinoids at any attainable exposure.^[6] Acute kidney and hepatic injury have also been documented in synthetic cannabinoid toxicity cases, particularly with newer-generation compounds.^[2]

Tolerance & dependence

Tolerance to cannabinoids develops through two CB₁ receptor-level mechanisms: desensitization — GRK-mediated phosphorylation and β-arrestin recruitment that functionally uncouples the receptor from its G protein — and downregulation — receptor internalization and reduced surface expression.^[7] Because all members converge on the same receptor system, tolerance developed to one cannabinoid predicts cross-tolerance to the others.

Human PET imaging in chronic daily cannabis users shows regionally selective CB₁ downregulation that returns toward normal after approximately four weeks of monitored abstinence.^[7] This biological reversibility frames the recovery trajectory.

Cannabis use disorder (CUD) is the formal dependence construct under DSM-5 and is predominantly psychological in character, with physical dependence present but mild relative to many other psychoactive classes.^[8] A meta-analysis of 47 studies found cannabis withdrawal syndrome in roughly half of regular or dependent users, with substantially higher rates in clinical samples than in the general population.^[9] Symptoms — irritability, anxiety, sleep disturbance, appetite changes, depressed mood, and somatic complaints — emerge within days of cessation and typically resolve within about two weeks.

Unlike alcohol or benzodiazepine withdrawal, cannabinoid withdrawal does not carry seizure risk, autonomic instability, or life-threatening cardiovascular complication.^[9] The category difference matters: cessation here is uncomfortable but not medically dangerous.

The cannabinoid class is a root grouping in this taxonomy and has no formal ancestor, child, or sibling classes. Functionally, however, it sits between several neighboring categories that are worth distinguishing.

It is not a classical CNS depressant. At typical phytocannabinoid exposures, CB₁ agonism does not produce the brainstem-mediated respiratory failure that defines the sedative-hypnotic class. The synthetic full agonists narrow this distinction at high exposures, but the underlying receptor system differs from GABA_A positive modulation (benzodiazepines, alcohol) and from μ-opioid agonism.

It is also not a serotonergic psychedelic. High-dose cannabinoids can produce perceptual disturbance that superficially resembles a psychedelic state, but the mechanism is CB₁-mediated suppression of GABAergic and glutamatergic signaling rather than 5-HT_2A agonism — mechanistically unrelated routes to perceptual alteration.^[1]

Within the class itself, the most important internal distinction is between phytocannabinoid partial agonists with co-occurring modulators — notably CBD — and synthetic full agonists that lack any such modulation. That contrast shapes nearly every page in the cannabinoid family and is the single most useful frame for reading them in context.